Review: Gene therapy in animal models of autosomal dominant retinitis pigmentosa

Molecular Vision

Volumn 18, Issue , 2012, Pages 2479-2496

  Rossmiller, Brian ^a   Mao, Haoyu ^a   Lewin, Alfred S ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILIARY NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LENTIVIRUS VECTOR; LIPOSOME; MICRORNA; NEUROTROPHIC FACTOR; PARVOVIRUS VECTOR; PIGMENT EPITHELIUM DERIVED FACTOR; RHODOPSIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; VALOSIN CONTAINING PROTEIN; ZINC FINGER PROTEIN;

AUTOSOMAL DOMINANT DISORDER; CARBOXY TERMINAL SEQUENCE; DISULFIDE BOND; ENDOPLASMIC RETICULUM; GENE LOCUS; GENE MUTATION; GENE REPRESSION; GENE THERAPY; GENE TRANSLOCATION; GENETIC ASSOCIATION; GLYCOSYLATION; HETEROZYGOSITY; MUELLER CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHOTORECEPTOR; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN MODIFICATION; PROTEIN STABILITY; PROTEIN TRANSPORT; RETINITIS PIGMENTOSA; REVIEW; RHO GENE; RNA INTERFERENCE; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM; ADENOVIRUS; ANIMAL; DISEASE MODEL; DOMINANT GENE; GENE EXPRESSION; GENE TRANSFER; GENE VECTOR; GENETIC TRANSCRIPTION; GENETICS; HUMAN; MOUSE; MUTATION; PATHOLOGY;

ADENOVIRIDAE; ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENES, DOMINANT; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MICE; MUTATION; RETINITIS PIGMENTOSA; RHODOPSIN; RNA INTERFERENCE; TRANSCRIPTION, GENETIC;

EID: 84867544047     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Review

References (200)

1. Sung CH, Chuang JZ. The cell biology of vision. J Cell Biol 2010; 190:953-63. [PMID: 20855501].
2. Hamel CP. Cone rod dystrophies. Orphanet J Rare Dis 2007; 2:7-[PMID: 17270046].
3. Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis 2006; 1:40-[PMID: 17032466].
4. Rakoczy EP, Kiel C, McKeone R, Stricher F, Serrano L. Analysis of disease-linked rhodopsin mutations based on structure, function, and protein stability calculations. J Mol Biol 2011; 405:584-606. [PMID: 21094163].
5. Bramall AN, Wright AF, Jacobson SG, McInnes RR. The genomic, biochemical, and cellular responses of the retina in inherited photoreceptor degenerations and prospects for the treatment of these disorders. Annu Rev Neurosci 2010; 33:441-72. [PMID: 20572772].
6. Dinculescu A, Glushakova L, Min SH, Hauswirth WW. Adeno-associated virus-vectored gene therapy for retinal disease. Hum Gene Ther 2005; 16:649-63. [PMID: 15960597].
7. Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, Hayes KC, Johnson CA, Anderson EJ, Gaudio AR, Willett WC, Schaefer EJ. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol 2004; 122:1297-305. [PMID: 15364708].
8. Krebs MP, Holden DC, Joshi P, Clark CL 3rd, Lee AH, Kaushal S. Molecular mechanisms of rhodopsin retinitis pigmentosa and the efficacy of pharmacological rescue. J Mol Biol 2010; 395:1063-78. [PMID: 19913029].
9. Tam LC, Kiang AS, Campbell M, Keaney J, Farrar GJ, Humphries MM, Kenna PF, Humphries P. Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90). Hum Mol Genet 2010; 19:4421-36. [PMID: 20817636].
10. Ohgane K, Dodo K, Hashimoto Y. Retinobenzaldehydes as proper-trafficking inducers of folding-defective P23H rhodopsin mutant responsible for retinitis pigmentosa. Bioorg Med Chem 2010; 18:7022-8. [PMID: 20805032].
11. Maeda T, Maeda A, Leahy P, Saperstein DA, Palczewski K. Effects of long-term administration of 9-cis-retinyl acetate on visual function in mice. Invest Ophthalmol Vis Sci 2009; 50:322-33. [PMID: 18708622].
12. Mendes HF, Zaccarini R, Cheetham ME. Pharmacological manipulation of rhodopsin retinitis pigmentosa. Adv Exp Med Biol 2010; 664:317-23. [PMID: 20238031].
13. Lee SY, Usui S, Zafar AB, Oveson BC, Jo YJ, Lu L, Masoudi S, Campochiaro PA. N-Acetylcysteine promotes long-term survival of cones in a model of retinitis pigmentosa. J Cell Physiol 2011; 226:1843-9. [PMID: 21506115].
14. Komeima K, Rogers BS, Campochiaro PA. Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. J Cell Physiol 2007; 213:809-15. [PMID: 17520694].
15. Obolensky A, Berenshtein E, Lederman M, Bulvik B, Alper-Pinus R, Yaul R, Deleon E, Chowers I, Chevion M, Banin E. Zinc-desferrioxamine attenuates retinal degeneration in the rd10 mouse model of retinitis pigmentosa. Free Radic Biol Med 2011; 51:1482-91. [PMID: 21824515].
16. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002; 16:669-94. [PMID: 12269861].
17. Sisk RA. Valproic acid treatment may be harmful in non-dominant forms of retinitis pigmentosa. Br J Ophthalmol 2012; 96:1154-5. [PMID: 22581401].
18. Sandberg MA, Rosner B, Weigel-DiFranco C, Berson EL. Lack of scientific rationale for use of valproic acid for retinitis pigmentosa. Br J Ophthalmol 2011; 95:744-[PMID: 21131379].
19. Roof DJ, Adamian M, Hayes A. Rhodopsin accumulation at abnormal sites in retinas of mice with a human P23H rhodopsin transgene. Invest Ophthalmol Vis Sci 1994; 35:4049-62. [PMID: 7960587].
20. Chen YF, Wang IJ, Lin LL, Chen MS. Examining rhodopsin retention in endoplasmic reticulum and intracellular localization in vitro and in vivo by using truncated rhodopsin fragments. J Cell Biochem 2011; 112:520-30. [PMID: 21268073].
21. Murray AR, Fliesler SJ, Al-Ubaidi MR. Rhodopsin: the functional significance of asn-linked glycosylation and other post-translational modifications. Ophthalmic Genet 2009; 30:109-20. [PMID: 19941415].
22. Frederick JM, Krasnoperova NV, Hoffmann K, Church-Kopish J, Ruther K, Howes K, Lem J, Baehr W. Mutant rhodopsin transgene expression on a null background. Invest Ophthalmol Vis Sci 2001; 42:826-33. [PMID: 11222546].
23. Wen XH, Shen L, Brush RS, Michaud N, Al-Ubaidi MR, Gurevich VV, Hamm HE, Lem J, Dibenedetto E, Anderson RE, Makino CL. Overexpression of rhodopsin alters the structure and photoresponse of rod photoreceptors. Biophys J 2009; 96:939-50. [PMID: 19186132].
24. Mendes HF, van der Spuy J, Chapple JP, Cheetham ME. Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. Trends Mol Med 2005; 11:177-85. [PMID: 15823756].
25. Kang MJ, Ryoo HD. Suppression of retinal degeneration in Drosophila by stimulation of ER-associated degradation. Proc Natl Acad Sci USA 2009; 106:17043-8. [PMID: 19805114].
26. Kaushal S, Ridge KD, Khorana HG. Structure and function in rhodopsin: the role of asparagine-linked glycosylation. Proc Natl Acad Sci USA 1994; 91:4024-8. [PMID: 8171029].
27. Sakami S, Maeda T, Bereta G, Okano K, Golczak M, Sumaroka A, Roman AJ, Cideciyan AV, Jacobson SG, Palczewski K. Probing mechanisms of photoreceptor degeneration in a new mouse model of the common form of autosomal dominant retinitis pigmentosa due to P23H opsin mutations. J Biol Chem 2011; 286:10551-67. [PMID: 21224384].
28. Kaushal S, Khorana HG. Structure and function in rhodopsin. 7. Point mutations associated with autosomal dominant retinitis pigmentosa. Biochemistry 1994; 33:6121-8. [PMID: 8193125].
29. Tam BM, Moritz OL. Dark rearing rescues P23H rhodopsin-induced retinal degeneration in a transgenic Xenopus laevis model of retinitis pigmentosa: a chromophore-dependent mechanism characterized by production of N-terminally truncated mutant rhodopsin. J Neurosci 2007; 27:9043-53. [PMID: 17715341].
30. White DA, Fritz JJ, Hauswirth WW, Kaushal S, Lewin AS. Increased sensitivity to light-induced damage in a mouse model of autosomal dominant retinal disease. Invest Ophthalmol Vis Sci 2007; 48:1942-51. [PMID: 17460245].
31. Lin JH, Li H, Yasumura D, Cohen HR, Zhang C, Panning B, Shokat KM, Lavail MM, Walter P. IRE1 signaling affects cell fate during the unfolded protein response. Science 2007; 318:944-9. [PMID: 17991856].
32. Gorbatyuk MS, Knox T, LaVail MM, Gorbatyuk OS, Noorwez SM, Hauswirth WW, Lin JH, Muzyczka N, Lewin AS. Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of BiP/Grp78. Proceedings of the National Academy of Sciences of the United States of America.107:5961-6.
33. Fletcher EL. Mechanisms of photoreceptor death during retinal degeneration. Optom Vis Sci 2010; 87:269-75. [PMID: 20019644].
34. Tam BM, Moritz OL. The role of rhodopsin glycosylation in protein folding, trafficking, and light-sensitive retinal degeneration. J Neurosci 2009; 29:15145-54. [PMID: 19955366].
35. Liu H, Wang M, Xia CH, Du X, Flannery JG, Ridge KD, Beutler B, Gong X. Severe retinal degeneration caused by a novel rhodopsin mutation. Invest Ophthalmol Vis Sci 2010; 51:1059-65. [PMID: 19741247].
36. Zhu L, Jang GF, Jastrzebska B, Filipek S, Pearce-Kelling SE, Aguirre GD, Stenkamp RE, Acland GM, Palczewski K. A naturally occurring mutation of the opsin gene (T4R) in dogs affects glycosylation and stability of the G protein-coupled receptor. J Biol Chem 2004; 279:53828-39. [PMID: 15459196].
37. Komáromy AM, Acland GM, Aguirre GD. Operating in the dark: a night-vision system for surgery in retinas susceptible to light damage. Arch Ophthalmol 2008; 126:714-7. [PMID: 18474785].
38. Zeiss CJ, Allore HG, Towle V, Tao W. CNTF induces dose-dependent alterations in retinal morphology in normal and rcd-1 canine retina. Exp Eye Res 2006; 82:395-404. [PMID: 16143329].
39. Cideciyan AV, Jacobson SG, Aleman TS, Gu D, Pearce-Kelling SE, Sumaroka A, Acland GM, Aguirre GD. In vivo dynamics of retinal injury and repair in the rhodopsin mutant dog model of human retinitis pigmentosa. Proc Natl Acad Sci USA 2005; 102:5233-8. [PMID: 15784735].
40. Hauck SM, Kinkl N, Deeg CA, Swiatek-de Lange M, Schoffmann S, Ueffing M. GDNF family ligands trigger indirect neuroprotective signaling in retinal glial cells. Mol Cell Biol 2006; 26:2746-57. [PMID: 16537917].
41. Ghosh F, Engelsberg K, English RV, Petters RM. Long-term neuroretinal full-thickness transplants in a large animal model of severe retinitis pigmentosa. Graefe's archive for clinical and experimental ophthalmology Albrecht Von Graefes Arch Klin Exp Ophthalmol 2007; 245:835-46.
42. Ross JW, Fernandez de Castro JP, Zhao J, Samuel M, Walters E, Rios C, Bray-Ward P, Jones BW, Marc RE, Wang W, Zhou L, Noel JM, McCall MA, DeMarco PJ, Prather RS, Kaplan HJ. Generation of an inbred miniature pig model of retinitis pigmentosa. Invest Ophthalmol Vis Sci 2012; 53:501-7. [PMID: 22247487].
43. Goto Y, Peachey NS, Ripps H, Naash MI. Functional abnormalities in transgenic mice expressing a mutant rhodopsin gene. Invest Ophthalmol Vis Sci 1995; 36:62-71. [PMID: 7822160].
44. Peachey NS, Ridder WH 3rd, Seeliger MW. Electrophysiologic assessment of the mouse visual system. Doc Ophthalmol 2007; 115:125-[PMID: 17823836].
45. Chadderton N, Millington-Ward S, Palfi A, O'Reilly M, Tuohy G, Humphries MM, Li T, Humphries P, Kenna PF, Farrar GJ. Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy. Mol Ther 2009; 17:593-9. [PMID: 19174761].
46. Mao H, Gorbatyuk MS, Rossmiller B, Hauswirth WW, Lewin AS. Long-term rescue of retinal structure and function by rhodopsin RNA replacement with a single adeno-associated viral vector in P23H RHO transgenic mice. Hum Gene Ther 2012; 23:356-66. [PMID: 22289036].
47. Prusky GT, Alam NM, Beekman S, Douglas RM. Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. Invest Ophthalmol Vis Sci 2004; 45:4611-6. [PMID: 15557474].
48. Kumar-Singh R, Chamberlain JS. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum Mol Genet 1996; 5:913-21. [PMID: 8817325].
49. Pang JJ, Dai X, Boye SE, Barone I, Boye SL, Mao S, Everhart D, Dinculescu A, Liu L, Umino Y, Lei B, Chang B, Barlow R, Strettoi E, Hauswirth WW. Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa. Mol Ther 2011; 19:234-42. [PMID: 21139570].
50. Alexander JJ, Umino Y, Everhart D, Chang B, Min SH, Li Q, Timmers AM, Hawes NL, Pang JJ, Barlow RB, Hauswirth WW. Restoration of cone vision in a mouse model of achromatopsia. Nat Med 2007; 13:685-7. [PMID: 17515894].
51. Pearson RA, Barber AC, Rizzi M, Hippert C, Xue T, West EL, Duran Y, Smith AJ, Chuang JZ, Azam SA, Luhmann UF, Benucci A, Sung CH, Bainbridge JW, Carandini M, Yau KW, Sowden JC, Ali RR. Restoration of vision after transplantation of photoreceptors. Nature 2012; 485:99-103. [PMID: 22522934].
52. Ruggeri M, Wehbe H, Jiao S, Gregori G, Jockovich ME, Hackam A, Duan Y, Puliafito CA. In vivo three-dimensional high-resolution imaging of rodent retina with spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 2007; 48:1808-14. [PMID: 17389515].
53. Gabriele ML, Ishikawa H, Schuman JS, Bilonick RA, Kim J, Kagemann L, Wollstein G. Reproducibility of spectral-domain optical coherence tomography total retinal thickness measurements in mice. Invest Ophthalmol Vis Sci 2010; 51:6519-23. [PMID: 20574022].
54. Huber G, Beck SC, Grimm C, Sahaboglu-Tekgoz A, Paquet-Durand F, Wenzel A, Humphries P, Redmond TM, Seeliger MW, Fischer MD. Spectral domain optical coherence tomography in mouse models of retinal degeneration. Invest Ophthalmol Vis Sci 2009; 50:5888-95. [PMID: 19661229].
55. Wang R, Jiang C, Ma J, Young MJ. Monitoring morphological changes in the retina of rhodopsin-/-mice with spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 2012; 53:3967-72. [PMID: 22618589].
56. Hawes NL, Smith RS, Chang B, Davisson M, Heckenlively JR, John SW. Mouse fundus photography and angiography: a catalogue of normal and mutant phenotypes. Mol Vis 1999; 5:22-[PMID: 10493779].
57. Chang B, Hawes NL, Hurd RE, Wang J, Howell D, Davisson MT, Roderick TH, Nusinowitz S, Heckenlively JR. Mouse models of ocular diseases. Vis Neurosci 2005; 22:587-93. [PMID: 16332269].
58. Pang JJ, Chang B, Kumar A, Nusinowitz S, Noorwez SM, Li J, Rani A, Foster TC, Chiodo VA, Doyle T, Li H, Malhotra R, Teusner JT, McDowell JH, Min SH, Li Q, Kaushal S, Hauswirth WW. Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. Mol Ther 2006; 13:565-72. [PMID: 16223604].
59. Faktorovich EG, Steinberg RH, Yasumura D, Matthes MT, LaVail MM. Photoreceptor degeneration in inherited retinal dystrophy delayed by basic fibroblast growth factor. Nature 1990; 347:83-6. [PMID: 2168521].
60. Léveillard T, Mohand-Said S, Lorentz O, Hicks D, Fintz AC, Clerin E, Simonutti M, Forster V, Cavusoglu N, Chalmel F, Dolle P, Poch O, Lambrou G, Sahel JA. Identification and characterization of rod-derived cone viability factor. Nat Genet 2004; 36:755-9. [PMID: 15220920].
61. Léveillard T, Mohand-Said S, Fintz AC, Lambrou G, Sahel JA. The search for rod-dependent cone viability factors, secreted factors promoting cone viability. Novartis Found Symp 2004; 255:117-27. [PMID: 14750600].
62. Yang Y, Mohand-Said S, Danan A, Simonutti M, Fontaine V, Clerin E, Picaud S, Léveillard T, Sahel JA. Functional cone rescue by RdCVF protein in a dominant model of retinitis pigmentosa. Mol Ther 2009; 17:787-95. [PMID: 19277021].
63. Caffé AR, Soderpalm AK, Holmqvist I, van Veen T. A combination of CNTF and BDNF rescues rd photoreceptors but changes rod differentiation in the presence of RPE in retinal explants. Invest Ophthalmol Vis Sci 2001; 42:275-82. [PMID: 11133879].
64. Yang PB, Seiler MJ, Aramant RB, Yan F, Mahoney MJ, Kitzes LM, Keirstead HS. Trophic factors GDNF and BDNF improve function of retinal sheet transplants. Exp Eye Res 2010; 91:727-38. [PMID: 20804751].
65. Tombran-Tink J, Shivaram SM, Chader GJ, Johnson LV, Bok D. Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurotrophic activity. J Neurosci 1995; 15:4992-5003. [PMID: 7623128].
66. Sugita Y, Becerra SP, Chader GJ, Schwartz JP. Pigment epithelium-derived factor (PEDF) has direct effects on the metabolism and proliferation of microglia and indirect effects on astrocytes. J Neurosci Res 1997; 49:710-8. [PMID: 9335258].
67. Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, Bush RA. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA 2006; 103:3896-901. [PMID: 16505355].
68. Thanos CG, Bell WJ, O'Rourke P, Kauper K, Sherman S, Stabila P, Tao W. Sustained secretion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based NT-501 intraocular device. Tissue Eng 2004; 10:1617-22. [PMID: 15684670].
69. Bok D, Yasumura D, Matthes MT, Ruiz A, Duncan JL, Chappelow AV, Zolutukhin S, Hauswirth W, LaVail MM. Effects of adeno-associated virus-vectored ciliary neurotrophic factor on retinal structure and function in mice with a P216L rds/peripherin mutation. Exp Eye Res 2002; 74:719-35. [PMID: 12126945].
70. Schlichtenbrede FC, MacNeil A, Bainbridge JW, Tschernutter M, Thrasher AJ, Smith AJ, Ali RR. Intraocular gene delivery of ciliary neurotrophic factor results in significant loss of retinal function in normal mice and in the Prph2Rd2/Rd2 model of retinal degeneration. Gene Ther 2003; 10:523-7. [PMID: 12621456].
71. Li Y, Tao W, Luo L, Huang D, Kauper K, Stabila P, Lavail MM, Laties AM, Wen R. CNTF induces regeneration of cone outer segments in a rat model of retinal degeneration. PLoS ONE 2010; 5:e9495-[PMID: 20209167].
72. Liang FQ, Aleman TS, Dejneka NS, Dudus L, Fisher KJ, Maguire AM, Jacobson SG, Bennett J. Long-term protection of retinal structure but not function using RAAV. CNTF in animal models of retinitis pigmentosa. Mol Ther 2001; 4:461-72. [PMID: 11708883].
73. McGee Sanftner LH, Abel H, Hauswirth WW, Flannery JG. Glial cell line derived neurotrophic factor delays photoreceptor degeneration in a transgenic rat model of retinitis pigmentosa. Mol Ther 2001; 4:622-9. [PMID: 11735347].
74. Frasson M, Picaud S, Leveillard T, Simonutti M, Mohand-Said S, Dreyfus H, Hicks D, Sabel J. Glial cell line-derived neurotrophic factor induces histologic and functional protection of rod photoreceptors in the rd/rd mouse. Invest Ophthalmol Vis Sci 1999; 40:2724-34. [PMID: 10509671].
75. Koeberle PD, Ball AK. Effects of GDNF on retinal ganglion cell survival following axotomy. Vision Res 1998; 38:1505-15. [PMID: 9667015].
76. Cheng H, Fu YS, Guo JW. Ability of GDNF to diminish free radical production leads to protection against kainate-induced excitotoxicity in hippocampus. Hippocampus 2004; 14:77-86. [PMID: 15058485].
77. Wu WC, Lai CC, Chen SL, Sun MH, Xiao X, Chen TL, Lin KK, Kuo SW, Tsao YP. Long-term safety of GDNF gene delivery in the retina. Curr Eye Res 2005; 30:715-22. [PMID: 16109652].
78. Yang PB, Seiler MJ, Aramant RB, Yan F, Mahoney MJ, Kitzes LM, Keirstead HS. Trophic factors GDNF and BDNF improve function of retinal sheet transplants. Exp Eye Res 2010; 91:727-38. [PMID: 20804751].
79. Yan Q, Wang J, Matheson CR, Urich JL. Glial cell line-derived neurotrophic factor (GDNF) promotes the survival of axotomized retinal ganglion cells in adult rats: comparison to and combination with brain-derived neurotrophic factor (BDNF). J Neurobiol 1999; 38:382-90. [PMID: 10022580].
80. Buch PK, MacLaren RE, Durán Y, Balaggan KS, MacNeil A, Schlichtenbrede FC, Smith AJ, Ali RR. In contrast to AAV-mediated Cntf expression, AAV-mediated Gdnf expression enhances gene replacement therapy in rodent models of retinal degeneration. Mol Ther 2006; 14:700-9. [PMID: 16872907].
81. Rodger J, Drummond ES, Hellstrom M, Robertson D, Harvey AR. Long-term gene therapy causes transgene-specific changes in the morphology of regenerating retinal ganglion cells. PLoS ONE 2012; 7:e31061-[PMID: 22347429].
82. Xue W, Cojocaru RI, Dudley VJ, Brooks M, Swaroop A, Sarthy VP. Ciliary neurotrophic factor induces genes associated with inflammation and gliosis in the retina: a gene profiling study of flow-sorted, Muller cells. PLoS ONE 2011; 6:e20326-[PMID: 21637858].
83. Wen R, Tao W, Li Y, Sieving PA. CNTF and retina. Prog Retin Eye Res 2012; 31:136-51. [PMID: 22182585].
84. Touchard E, Heiduschka P, Berdugo M, Kowalczuk L, Bigey P, Chahory S, Gandolphe C, Jeanny JC, Behar-Cohen F. Non-viral gene therapy for GDNF production in RCS rat: the crucial role of the plasmid dose. Gene Ther 2012; 19:886-98. [PMID: 21993171].
85. Olsson JE, Gordon JW, Pawlyk BS, Roof D, Hayes A, Molday RS, Mukai S, Cowley GS, Berson EL, Dryja TP. Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa. Neuron 1992; 9:815-30. [PMID: 1418997].
86. Tan E, Wang Q, Quiambao AB, Xu X, Qtaishat NM, Peachey NS, Lem J, Fliesler SJ, Pepperberg DR, Naash MI, Al-Ubaidi MR. The relationship between opsin overexpression and photoreceptor degeneration. Invest Ophthalmol Vis Sci 2001; 42:589-600. [PMID: 11222515].
87. Lem J, Krasnoperova NV, Calvert PD, Kosaras B, Cameron DA, Nicolo M, Makino CL, Sidman RL. Morphological, physiological, and biochemical changes in rhodopsin knockout mice. Proc Natl Acad Sci USA 1999; 96:736-41. [PMID: 9892703].
88. Wilson JH, Wensel TG. The nature of dominant mutations of rhodopsin and implications for gene therapy. Mol Neurobiol 2003; 28:149-58. [PMID: 14576453].
89. Mao H, James T Jr, Schwein A, Shabashvili AE, Hauswirth WW, Gorbatyuk MS, Lewin AS. AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa. Hum Gene Ther 2011; 22:567-75. [PMID: 21126223].
90. Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 2010; 28:570-9. [PMID: 20833440].
91. Gorbatyuk M, Justilien V, Liu J, Hauswirth WW, Lewin AS. Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery. Vision Res 2007; 47:1202-8. [PMID: 17292939].
92. Gorbatyuk M, Justilien V, Liu J, Hauswirth WW, Lewin AS. Preservation of photoreceptor morphology and function in P23H rats using an allele independent ribozyme. Exp Eye Res 2007; 84:44-52. [PMID: 17083931].
93. Kiang AS, Palfi A, Ader M, Kenna PF, Millington-Ward S, Clark G, Kennan A, O'reilly M, Tam LC, Aherne A, McNally N, Humphries P, Farrar GJ. Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation-independent approach. Mol Ther 2005; 12:555-61. [PMID: 15967729].
94. Cashman SM, Binkley EA, Kumar-Singh R. Towards mutation-independent silencing of genes involved in retinal degeneration by RNA interference. Gene Ther 2005; 12:1223-8. [PMID: 15877050].
95. Smith AJ, Bainbridge JW, Ali RR. Prospects for retinal gene replacement therapy. Trends in genetics TIG 2009; 25:156-65. [PMID: 19303164].
96. Sullivan JM, Pietras KM, Shin BJ, Misasi JN. Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa. Mol Vis 2002; 8:102-13. [PMID: 11961505].
97. Millington-Ward S, Chadderton N, O'Reilly M, Palfi A, Goldmann T, Kilty C, Humphries M, Wolfrum U, Bennett J, Humphries P, Kenna PF, Farrar GJ. Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. Mol Ther 2011; 19:642-9. [PMID: 21224835].
98. Li C, Xiao P, Gray SJ, Weinberg MS, Samulski RJ. Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins. Proc Natl Acad Sci USA 2011; 108:14258-63. [PMID: 21844342].
99. O'Reilly M, Palfi A, Chadderton N, Millington-Ward S, Ader M, Cronin T, Tuohy T, Auricchio A, Hildinger M, Tivnan A, McNally N, Humphries MM, Kiang AS, Humphries P, Kenna PF, Farrar GJ. RNA interference-mediated suppression and replacement of human rhodopsin in vivo. Am J Hum Genet 2007; 81:127-35. [PMID: 17564969].
100. Boudreau RL, Monteys AM, Davidson BL. Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA 2008; 14:1834-44. [PMID: 18697922].
101. McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I, Gilmore BL, Burstein H, Peluso RW, Polisky B, Carter BJ, Davidson BL. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 2008; 105:5868-73. [PMID: 18398004].
102. Beer S, Bellovin DI, Lee JS, Komatsubara K, Wang LS, Koh H, Börner K, Storm TA, Davis CR, Kay MA, Felsher DW, Grimm D. Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. Mol Ther 2010; 18:161-70. [PMID: 19844192].
103. Zeng Y, Wagner EJ, Cullen BR. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 2002; 9:1327-33. [PMID: 12086629].
104. Sin O, Mabiala P, Liu Y, Sun Y, Hu T, Liu Q, Guo D. Gene silencing efficiency and INF-ß induction effects of splicing miRNA 155-based artificial miRNA with pre-miRNA stem-loop structures. Biochem Genet 2012; 50:112-21. [PMID: 22119863].
105. Liu Z, Sall A, Yang D. MicroRNA: An emerging therapeutic target and intervention tool. Int J Mol Sci 2008; 9:978-99. [PMID: 19325841].
106. Chung KH, Hart CC, Al-Bassam S, Avery A, Taylor J, Patel PD, Vojtek AB, Turner DL. Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res 2006; 34:e53-[PMID: 16614444].
107. Chen SC, Stern P, Guo Z, Chen J. Expression of multiple artificial microRNAs from a chicken miRNA126-based lentiviral vector. PLoS ONE 2011; 6:e22437-[PMID: 21789258].
108. Borel F, van Logtenstein R, Koornneef A, Maczuga P, Ritsema T, Petry H, van Deventer SJ, Jansen PL, Konstantinova P. In vivo knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs. J RNAi Gene Silencing. 2011; 7:434-42. [PMID: 21769296].
109. Shan Z, Lin Q, Deng C, Li X, Huang W, Tan H, Fu Y, Yang M, Yu XY. An efficient method to enhance gene silencing by using precursor microRNA designed small hairpin RNAs. Mol Biol Rep 2009; 36:1483-9. [PMID: 18758992].
110. Furukawa N, Sakurai F, Katayama K, Seki N, Kawabata K, Mizuguchi H. Optimization of a microRNA expression vector for function analysis of microRNA. J Control Release 2011; 150:94-101. [PMID: 21146569].
111. Boden D, Pusch O, Silbermann R, Lee F, Tucker L, Ramratnam B. Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res 2004; 32:1154-8. [PMID: 14966264].
112. Hu T, Fu Q, Chen P, Ma L, Sin O, Guo D. Construction of an artificial MicroRNA expression vector for simultaneous inhibition of multiple genes in mammalian cells. Int J Mol Sci 2009; 10:2158-68. [PMID: 19564946].
113. Chen S, Ni M, Yu B, Lv T, Lu M, Gong F. Construction and identification of a human liver specific microRNA eukaryotic expression vector. Cell Mol Immunol 2007; 4:473-7. [PMID: 18163960].
114. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci USA 2005; 102:13212-7. [PMID: 16141338].
115. Mueller C, Tang Q, Gruntman A, Blomenkamp K, Teckman J, Song L, Zamore PD, Flotte TR. Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles. Mol Ther 2012; 20:590-600. [PMID: 22252449].
116. Martin JN, Wolken N, Brown T, Dauer WT, Ehrlich ME, Gonzalez-Alegre P. Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design. Gene Ther 2011; 18:666-73. [PMID: 21368900].
117. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441:537-41. [PMID: 16724069].
118. Kleinman ME, Kaneko H, Cho WG, Dridi S, Fowler BJ, Blandford AD, Albuquerque RJ, Hirano Y, Terasaki H, Kondo M, Fujita T, Ambati BK, Tarallo V, Gelfand BD, Bogdanovich S, Baffi JZ, Ambati J. Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. Mol Ther 2012; 20:101-8. [PMID: 21988875].
119. Sioud M. RNA interference and innate immunity. Adv Drug Deliv Rev 2007; 59:153-63. [PMID: 17459518].
120. Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, Baskerville S, Maksimova E, Robinson K, Karpilow J, Marshall WS, Khvorova A. 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 2006; 3:199-204. [PMID: 16489337].
121. Grimm D, Kay MA. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest 2007; 117:3633-41. [PMID: 18060021].
122. Robbins M, Judge A, Ambegia E, Choi C, Yaworski E, Palmer L, McClintock K, MacLachlan I. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 2008; 19:991-9. [PMID: 18713023].
123. Hauswirth WW, Lewin AS. Ribozyme uses in retinal gene therapy. Prog Retin Eye Res 2000; 19:689-710. [PMID: 11029552].
124. Amarzguioui M, Prydz H. Hammerhead ribozyme design and application. Cell Mol Life Sci 1998; 54:1175-202. [PMID: 9849614].
125. Norris JS, Hoel B, Voeks D, Maggouta F, Dahm M, Pan W, Clawson G. Design and testing of ribozymes for cancer gene therapy. Adv Exp Med Biol 2000; 465:293-301. [PMID: 10810634].
126. Abdelmaksoud HE, Yau EH, Zuker M, Sullivan JM. Development of lead hammerhead ribozyme candidates against human rod opsin mRNA for retinal degeneration therapy. Exp Eye Res 2009; 88:859-79. [PMID: 19094986].
127. Sullivan JM, Yau EH, Taggart RT, Butler MC, Kolniak TA. Bottlenecks in development of retinal therapeutic post-transcriptional gene silencing agents. Vision Res 2008; 48:453-69. [PMID: 17976683].
128. Lewin AS, Drenser KA, Hauswirth WW, Nishikawa S, Yasumura D, Flannery JG, LaVail MM. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nat Med 1998; 4:967-71. [PMID: 9701253].
129. Chakraborty D, Whalen P, Lewin AS, Naash MI. In vitro analysis of ribozyme-mediated knockdown of an ADRP associated rhodopsin mutation. Adv Exp Med Biol 2008; 613:97-106. [PMID: 18188933].
130. O'Neill B, Millington-Ward S, O'Reilly M, Tuohy G, Kiang AS, Kenna PF, Humphries P, Farrar GJ. Ribozyme-based therapeutic approaches for autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci 2000; 41:2863-9. [PMID: 10967039].
131. Cornu TI, Cathomen T. Quantification of zinc finger nuclease-associated toxicity. Methods Mol Biol 2010; 649:237-45. [PMID: 20680838].
132. Mussolino C, Sanges D, Marrocco E, Bonetti C, Di Vicino U, Marigo V, Auricchio A, Meroni G, Surace EM. Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa. EMBO Mol Med. 2011; 3:118-28. [PMID: 21268285].
133. Cradick TJ, Ambrosini G, Iseli C, Bucher P, McCaffrey AP. ZFN-site searches genomes for zinc finger nuclease target sites and off-target sites. BMC Bioinformatics 2011; 12:152-[PMID: 21569489].
134. Mussolino C, Sanges D, Marrocco E, Bonetti C, Di Vicino U, Marigo V, Auricchio A, Meroni G, Surace EM. Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa. EMBO Mol Med. 2011; 3:118-28. [PMID: 21268285].
135. Otteson DC, Lai H, Liu Y, Zack DJ. Zinc-finger domains of the transcriptional repressor KLF15 bind multiple sites in rhodopsin and IRBP promoters including the CRS-1 and G-rich repressor elements. BMC Mol Biol 2005; 6:15-[PMID: 15963234].
136. Greenwald DL, Cashman SM, Kumar-Singh R. Engineered zinc finger nuclease-mediated homologous recombination of the human rhodopsin gene. Invest Ophthalmol Vis Sci 2010; 51:6374-80. [PMID: 20671268].
137. Christian M, Cermak T, Doyle EL, Schmidt C, Zhang F, Hummel A, Bogdanove AJ, Voytas DF. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 2010; 186:757-61. [PMID: 20660643].
138. Li T, Huang S, Zhao X, Wright DA, Carpenter S, Spalding MH, Weeks DP, Yang B. Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes. Nucleic Acids Res 2011; 39:6315-25. [PMID: 21459844].
139. Cermak T, Doyle EL, Christian M, Wang L, Zhang Y, Schmidt C, Baller JA, Somia NV, Bogdanove AJ, Voytas DF. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res 2011; 39:e82-[PMID: 21493687].
140. Wood AJ, Lo TW, Zeitler B, Pickle CS, Ralston EJ, Lee AH, Amora R, Miller JC, Leung E, Meng X, Zhang L, Rebar EJ, Gregory PD, Urnov FD, Meyer BJ. Targeted genome editing across species using ZFNs and TALENs. Science 2011; 333:307-[PMID: 21700836].
141. Carroll D. Progress and prospects: zinc-finger nucleases as gene therapy agents. Gene Ther 2008; 15:1463-8. [PMID: 18784746].
142. Miller JC, Holmes MC, Wang J, Guschin DY, Lee YL, Rupniewski I, Beausejour CM, Waite AJ, Wang NS, Kim KA, Gregory PD, Pabo CO, Rebar EJ. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 2007; 25:778-85. [PMID: 17603475].
143. Pruett-Miller SM, Reading DW, Porter SN, Porteus MH. Attenuation of zinc finger nuclease toxicity by small-molecule regulation of protein levels. PLoS Genet 2009; 5:e1000376-[PMID: 19214211].
144. Punzo C, Kornacker K, Cepko CL. Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa. Nat Neurosci 2009; 12:44-52. [PMID: 19060896].
145. Zhao C, Yasumura D, Li X, Matthes M, Lloyd M, Nielsen G, Ahern K, Snyder M, Bok D, Dunaief JL, LaVail MM, Vollrath D. mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice. J Clin Invest 2011; 121:369-83. [PMID: 21135502].
146. Griciuc A, Aron L, Piccoli G, Ueffing M. Clearance of Rhodopsin(P23H) aggregates requires the ERAD effector VCP. Biochim Biophys Acta 2010; 1803:424-34. [PMID: 20097236].
147. Noorwez SM, Ostrov DA, McDowell JH, Krebs MP, Kaushal S. A high-throughput screening method for small-molecule pharmacologic chaperones of misfolded rhodopsin. Invest Ophthalmol Vis Sci 2008; 49:3224-30. [PMID: 18378578].
148. Han Z, Conley SM, Naash MI. AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects. Invest Ophthalmol Vis Sci 2011; 52:3051-9. [PMID: 21558483].
149. Bloquel C, Bourges JL, Touchard E, Berdugo M, BenEzra D, Behar-Cohen F. Non-viral ocular gene therapy: potential ocular therapeutic avenues. Adv Drug Deliv Rev 2006; 58:1224-42. [PMID: 17095114].
150. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, Samulski RJ. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76:791-801. [PMID: 11752169].
151. Doi K, Hargitai J, Kong J, Tsang SH, Wheatley M, Chang S, Goff S, Gouras P. Lentiviral transduction of green fluorescent protein in retinal epithelium: evidence of rejection. Vision Res 2002; 42:551-8. [PMID: 11853772].
152. van Adel BA, Kostic C, Deglon N, Ball AK, Arsenijevic Y. Delivery of ciliary neurotrophic factor via lentiviral-mediated transfer protects axotomized retinal ganglion cells for an extended period of time. Hum Gene Ther 2003; 14:103-15. [PMID: 12614562].
153. Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 1992; 158:97-129. [PMID: 1316261].
154. Grimm D, Kay MA, Kleinschmidt JA. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 2003; 7:839-50. [PMID: 12788658].
155. Peden CS, Burger C, Muzyczka N, Mandel RJ. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 2004; 78:6344-59. [PMID: 15163728].
156. Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, Reier PJ, Mandel RJ, Muzyczka N. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 2004; 10:302-17. [PMID: 15294177].
157. Stieger K, Lorenz B. Gene therapy for vision loss-recent developments. Discov Med 2010; 10:425-33. [PMID: 21122474].
158. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL, Windsor EA, Conlon TJ, Sumaroka A, Pang JJ, Roman AJ, Byrne BJ, Jacobson SG. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 2009; 20:999-1004. [PMID: 19583479].
159. Sun X, Pawlyk B, Xu X, Liu X, Bulgakov OV, Adamian M, Sandberg MA, Khani SC, Tan MH, Smith AJ, Ali RR, Li T. Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations. Gene Ther 2010; 17:117-31. [PMID: 19710705].
160. Dinculescu A, Estreicher J, Zenteno JC, Aleman TS, Schwartz SB, Huang WC, Roman AJ, Sumaroka A, Li Q, Deng WT, Min SH, Chiodo VA, Neeley A, Liu X, Shu X, Matias-Florentino M, Buentello-Volante B, Boye SL, Cideciyan AV, Hauswirth WW, Jacobson SG. Gene therapy for retinitis pigmentosa caused by MFRP mutations: human phenotype and preliminary proof of concept. Hum Gene Ther 2012; 23:367-76. [PMID: 22142163].
161. Mussolino C, della Corte M, Rossi S, Viola F, Di Vicino U, Marrocco E, Neglia S, Doria M, Testa F, Giovannoni R, Crasta M, Giunti M, Villani E, Lavitrano M, Bacci ML, Ratiglia R, Simonelli F, Auricchio A, Surace EM. AAV-mediated photoreceptor transduction of the pig cone-enriched retina. Gene Ther 2011; 18:637-45. [PMID: 21412286].
162. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358:2231-9. [PMID: 18441371].
163. Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S, Roman AJ, Pang JJ, Sumaroka A, Windsor EA, Wilson JM, Flotte TR, Fishman GA, Heon E, Stone EM, Byrne BJ, Jacobson SG, Hauswirth WW. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA 2008; 105:15112-7. [PMID: 18809924].
164. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL, Windsor EA, Conlon TJ, Sumaroka A, Roman AJ, Byrne BJ, Jacobson SG. Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med 2009; 361:725-7. [PMID: 19675341].
165. Dejneka NS, Surace EM, Aleman TS, Cideciyan AV, Lyubarsky A, Savchenko A, Redmond TM, Tang W, Wei Z, Rex TS, Glover E, Maguire AM, Pugh EN Jr, Jacobson SG, Bennett J. In utero gene therapy rescues vision in a murine model of congenital blindness. Mol Ther 2004; 9:182-8. [PMID: 14759802].
166. Komáromy AM, Alexander JJ, Cooper AE, Chiodo VA, Glushakova LG, Acland GM, Hauswirth WW, Aguirre GD. Targeting gene expression to cones with human cone opsin promoters in recombinant AAV. Gene Ther 2008; 15:1049-55. [PMID: 18337838].
167. Park TK, Wu Z, Kjellstrom S, Zeng Y, Bush RA, Sieving PA, Colosi P. Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse. Gene Ther 2009; 16:916-26. [PMID: 19458650].
168. Lai Y, Yue Y, Duan D. Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb. Mol Ther 2010; 18:75-9. [PMID: 19904238].
169. Tosi J, Sancho-Pelluz J, Davis RJ, Hsu CW, Wolpert KV, Sengillo JD, Lin CS, Tsang SH. Lentivirus-mediated expression of cDNA and shRNA slows degeneration in retinitis pigmentosa. Exp Biol Med (Maywood) 2011; 236:1211-7. [PMID: 21885480].
170. Kay MA. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 2011; 12:316-28. [PMID: 21468099].
171. Auricchio A, Kobinger G, Anand V, Hildinger M, O'Connor E, Maguire AM, Wilson JM, Bennett J. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet 2001; 10:3075-81. [PMID: 11751689].
172. Balaggan KS, Binley K, Esapa M, Iqball S, Askham Z, Kan O, Tschernutter M, Bainbridge JW, Naylor S, Ali RR. Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors. J Gene Med 2006; 8:275-85. [PMID: 16299834].
173. Sweigard JH, Cashman SM, Kumar-Singh R. Adenovirus vectors targeting distinct cell types in the retina. Invest Ophthalmol Vis Sci 2010; 51:2219-28. [PMID: 19892875].
174. Murakami Y, Ikeda Y, Yonemitsu Y, Tanaka S, Kondo H, Okano S, Kohno R, Miyazaki M, Inoue M, Hasegawa M, Ishibashi T, Sueishi K. Newly-developed Sendai virus vector for retinal gene transfer: reduction of innate immune response via deletion of all envelope-related genes. J Gene Med 2008; 10:165-76. [PMID: 18074401].
175. Lowenstein PR, Mandel RJ, Xiong WD, Kroeger K, Castro MG. Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther 2007; 7:347-60. [PMID: 17979681].
176. Li Q, Miller R, Han PY, Pang J, Dinculescu A, Chiodo V, Hauswirth WW. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis 2008; 14:1760-9. [PMID: 18836574].
177. Dalkara D, Byrne LC, Lee T, Hoffmann NV, Schaffer DV, Flannery JG. Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9. Gene Ther 2012; 19:176-81. [PMID: 22011645].
178. Xu J, Ganesh S, Amiji M. Non-condensing polymeric nanoparticles for targeted gene and siRNA delivery. Int J Pharm 2012; 427:21-34. [PMID: 21621597].
179. Yurek DM, Fletcher AM, Smith GM, Seroogy KB, Ziady AG, Molter J, Kowalczyk TH, Padegimas L, Cooper MJ. Long-term transgene expression in the central nervous system using DNA nanoparticles. Mol Ther 2009; 17:641-50. [PMID: 19223866].
180. Ishikawa H, Takano M, Matsumoto N, Sawada H, Ide C, Mimura O, Dezawa M. Effect of GDNF gene transfer into axotomized retinal ganglion cells using in vivo electroporation with a contact lens-type electrode. Gene Ther 2005; 12:289-98. [PMID: 15616607].
181. Matsuda T, Cepko CL. Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc Natl Acad Sci USA 2004; 101:16-22. [PMID: 14603031].
182. Sanuki R, Onishi A, Koike C, Muramatsu R, Watanabe S, Muranishi Y, Irie S, Uneo S, Koyasu T, Matsui R, Cherasse Y, Urade Y, Watanabe D, Kondo M, Yamashita T, Furukawa T. miR-124a is required for hippocampal axogenesis and retinal cone survival through Lhx2 suppression. Nat Neurosci 2011; 14:1125-34. [PMID: 21857657].
183. Conley SM, Naash MI. Nanoparticles for retinal gene therapy. Prog Retin Eye Res 2010; 29:376-97. [PMID: 20452457].
184. Kimura T, Nibe Y, Funamoto S, Okada M, Furuzono T, Ono T, Yoshizawa H, Fujisato T, Nam K, Kishida A. Preparation of a Nanoscaled Poly(vinyl alcohol)/Hydroxyapatite/DNA Complex Using High Hydrostatic Pressure Technology for In Vitro and In Vivo Gene Delivery. J Drug Deliv 2011; 2011:962743-[PMID: 21773048].
185. Cai X, Nash Z, Conley SM, Fliesler SJ, Cooper MJ, Naash MI. A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. PLoS ONE 2009; 4:e5290-[PMID: 19390689].
186. Binder C, Read SP, Cashman SM, Kumar-Singh R. Nuclear targeted delivery of macromolecules to retina and cornea. J Gene Med 2011; 13:158-70. [PMID: 21344542].
187. Ding XQ, Quiambao AB, Fitzgerald JB, Cooper MJ, Conley SM, Naash MI. Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina. PLoS ONE 2009; 4:e7410-[PMID: 19823583].
188. Jo DH, Lee TG, Kim JH. Nanotechnology and nanotoxicology in retinopathy. Int J Mol Sci 2011; 12:8288-301. [PMID: 22174664].
189. Wielgus AR, Roberts JE. Retinal Photodamage by Endogenous and Xenobiotic Agents Photochem Photobiol 2012; xx:xx-xx. [PMID: 22582903].
190. Li M, Jayandharan GR, Li B, Ling C, Ma W, Srivastava A, Zhong L. High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy. Hum Gene Ther 2010; 21:1527-43. [PMID: 20507237].
191. Surace EM, Auricchio A. Versatility of AAV vectors for retinal gene transfer. Vision Res 2008; 48:353-9. [PMID: 17923143].
192. McCarty DM. Self-complementary AAV vectors; advances and applications. Mol Ther 2008; 16:1648-56. [PMID: 18682697].
193. Pang J, Boye SE, Lei B, Boye SL, Everhart D, Ryals R, Umino Y, Rohrer B, Alexander J, Li J, Dai X, Li Q, Chang B, Barlow R, Hauswirth WW. Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency. Gene Ther 2010; 17:815-26. [PMID: 20237510].
194. Kong F, Li W, Li X, Zheng Q, Dai X, Zhou X, Boye SL, Hauswirth WW, Qu J, Pang JJ. Self-complementary AAV5 vector facilitates quicker transgene expression in photoreceptor and retinal pigment epithelial cells of normal mouse. Exp Eye Res 2010; 90:546-54. [PMID: 20138034].
195. Koilkonda RD, Hauswirth WW, Guy J. Efficient expression of self-complementary AAV in ganglion cells of the ex vivo primate retina. Mol Vis 2009; 15:2796-802. [PMID: 20019878].
196. Gray SJ, Foti SB, Schwartz JW, Bachaboina L, Taylor-Blake B, Coleman J, Ehlers MD, Zylka MJ, McCown TJ, Samulski RJ. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther 2011; 22:1143-53. [PMID: 21476867].
197. Simons DL, Boye SL, Hauswirth WW, Wu SM. Gene therapy prevents photoreceptor death and preserves retinal function in a Bardet-Biedl syndrome mouse model. Proc Natl Acad Sci USA 2011; 108:6276-81. [PMID: 21444805].
198. Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M, Herzog RW, Zolotukhin I, Warrington KH Jr, Weigel-Van Aken KA, Hobbs JA, Zolotukhin S, Muzyczka N, Srivastava A. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 2008; 105:7827-32. [PMID: 18511559].
199. Zhong L, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M, Herzog RW, Weigel-Van Aken KA, Hobbs JA, Zolotukhin S, Muzyczka N, Srivastava A. Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology 2008; 381:194-202. [PMID: 18834608].
200. Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R, Wang L, Castle MJ, Maguire AC, Grant R, Wolfe JH, Wilson JM, Bennett J. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3:88ra54-[PMID: 21697530].